Heron Therapeutics (NASDAQ:HRTX – Get Free Report) posted its quarterly earnings results on Monday. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.03), FiscalAI reports. Heron Therapeutics had a negative net margin of 14.55% and a negative return on equity of 277.36%. The company had revenue of $35.25 million for the quarter, compared to the consensus estimate of $37.50 million.
Heron Therapeutics Stock Performance
Shares of NASDAQ HRTX opened at $0.31 on Friday. The stock’s fifty day simple moving average is $0.33 and its 200 day simple moving average is $0.65. The stock has a market capitalization of $59.08 million, a price-to-earnings ratio of -2.59 and a beta of 1.65. The company has a quick ratio of 1.51, a current ratio of 2.33 and a debt-to-equity ratio of 32.59. Heron Therapeutics has a 52-week low of $0.26 and a 52-week high of $1.57.
Analysts Set New Price Targets
A number of analysts have commented on the stock. HC Wainwright downgraded shares of Heron Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 11th. Wall Street Zen upgraded shares of Heron Therapeutics to a “sell” rating in a report on Saturday, August 8th. Zacks Research upgraded shares of Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, August 3rd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Thursday, October 15th. Three research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and an average price target of $2.00.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and marketing medicines for acute care and oncology supportive care. Its products are designed to address unmet needs such as postoperative pain and chemotherapy-induced nausea and vomiting. The company’s portfolio includes ZYNRELEF, an extended-release solution combining bupivacaine and meloxicam for the management of postoperative pain in adults. Heron also markets CINVANTI, an injectable formulation of aprepitant used as part of a combination regimen to help prevent acute and delayed nausea and vomiting associated with highly or moderately emetogenic cancer chemotherapy.
Read More
- Five stocks we like better than Heron Therapeutics
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
